> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Studying Diflucan Miscarriage Risk
- URL: https://www.fdaweb.com/fda-studying-diflucan-miscarriage-risk/
- Published: 2016-04-26T12:00:00.000Z
- Updated: 2026-09-14T20:57:35.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135495

FDA says it is evaluating the results of a Danish study that concluded there is a possible increased risk of miscarriage with use of oral fluconazone (Diflucan) for yeast infections. An agency [safety communication](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) says it also is reviewing additional data and will communicate final conclusions and recommendations when the review is complete.

According to the notice, the drug’s current labeling says that data available from studies in people do not suggest an increased risk of problems during pregnancy or abnormalities in developing babies when women are exposed to a single 150 mg dose of oral fluconazole to treat vaginal yeast infections.

However, the notice says, higher doses of oral fluconazole (400-800 mg/day) taken by pregnant women multiple times, rather than as a single dose, have resulted in reports of abnormalities at birth. In the Danish study, it says, most of the oral fluconazole use appeared to be one or two 150 mg doses.

FDA says it advises cautious prescribing of oral fluconazole in pregnancy until its review is complete and more is understood about the study and other available data.